In key win, AbbVie lands FDA approval for Allergan's blurred-vision eye drop
AbbVie’s age-related blurry vision drug for aging adults was given the OK by the FDA Friday, making it the first eye drop to treat an eye condition that affects 128 million Americans.
Formerly AGN-190584, the drug has proven a bright spot in Allergan’s pipeline since AbbVie bought it out for $63 billion, which has seen more setbacks than wins.
The daily prescription eye drop is approved to treat presbyopia. Vuity is a formulation of pilocarpine, a well-known drug for intraocular pressure and various types of glaucoma, among other uses. Allergan had deployed a different delivery method that promised to make the drug better tolerated.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.